Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NAMS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNewAmsterdam Pharma appoints Robert W. Gunning as principal accounting officer
Filed August 14, 2026 · Period ending August 10, 2026 · ~1 min read
Key Changes
-
medium
Robert W. Gunning appointed principal accounting officer and VP Controller effective August 10, 2026, succeeding Louise Kooij (departing August 31). Gunning brings prior controller and CFO experience from Y-mAbs Therapeutics, Excision Biotherapeutics, and Advanced Accelerator Applications.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
Compensation package includes $375,000 annual base salary and 30% target annual bonus (prorated first year), plus equity grants of 3,200 RSUs and options for 14,000 ordinary shares under the 2024 Inducement Plan.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
NewAmsterdam Pharma appointed Robert W. Gunning as principal accounting officer and Vice President, Controller, effective August 10, 2026. Gunning succeeds Louise Kooij, whose previously announced departure is effective August 31, 2026.
The appointment fills a key financial reporting role with an experienced executive who has held controller and CFO positions at biopharmaceutical companies including Y-mAbs Therapeutics, Excision Biotherapeutics, and Advanced Accelerator Applications.
Gunning's compensation package includes a $375,000 base salary, eligibility for a 30% target annual bonus (prorated for his first partial year), and equity awards consisting of 3,200 restricted stock units and stock options to purchase 14,000 ordinary shares under the company's 2024 Inducement Plan. The equity grants follow NewAmsterdam's standard new hire practices. This is a routine governance matter with no immediate concerns for shareholders.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 17, 2026 · How we verify